RT Journal Article
SR Electronic
T1 Reduced neutralization of SARS-CoV-2 B.1.617 variant by inactivated and RBD-subunit vaccine
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.07.09.451732
DO 10.1101/2021.07.09.451732
A1 Jie Hu
A1 Xiao-yu Wei
A1 Jin Xiang
A1 Pai Peng
A1 Feng-li Xu
A1 Kang Wu
A1 Fei-yang Luo
A1 Ai-shun Jin
A1 Liang Fang
A1 Bei-zhong Liu
A1 Kai Wang
A1 Ni Tang
A1 Ai-Long Huang
YR 2021
UL http://biorxiv.org/content/early/2021/07/09/2021.07.09.451732.abstract
AB Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Spike protein that mediates coronavirus entry into host cells is a major target for COVID-19 vaccines and antibody therapeutics. However, multiple variants of SARS-CoV-2 have emerged, which may potentially compromise vaccine effectiveness. Using a pseudovirus-based assay, we evaluated SARS-CoV-2 cell entry mediated by the viral Spike B.1.617 and B.1.1.7 variants. We also compared the neutralization ability of monoclonal antibodies from convalescent sera and neutralizing antibodies (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, compared to D614G and B.1.1.7 variants, B.1.617 shows enhanced viral entry and membrane fusion, as well as more resistant to antibody neutralization. These findings have important implications for understanding viral infectivity and for immunization policy against SARS-CoV-2 variants.Competing Interest StatementThe authors have declared no competing interest.